Homeopathic Treatment of Premenstrual Syndrome

Summary

The proposed study will focus on premenstrual syndrome (PMS) symptom alleviation for women diagnosed as suffering from the syndrome with the DRSP questionnaire.

The women will be treated with Homeopatic remedies. The improvement of PMS symptoms will be evaluated using the Daily Record of Severity of Problems questionnaire (DRSP). The questionnaire will be completed daily by women for 2 months prior to receiving the treatment and for 3 months following treatment with a single dose of the homeopathy treatment.

Conditions

• Premenstrual Syndrome-PMS

Interventions

DRUG

Natrum muriaticum 30C

3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Lachesis 30C

3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Sepia 30C

3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Nux vomica 30C

3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Pulsatilla 30C

3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Folliculinum 30C

3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Placebo Natrum muriaticum

3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Placebo Lachesis

3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Placebo Sepia

3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Placebo Nux vomica

3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Placebo pulsatilla

3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.

DRUG

Placebo Folliculinum

3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.

Sponsors & Collaborators

• Shaare Zedek Medical Center

  lead OTHER

Principal Investigators

• Menachem Oberbaum, MD · The Center for Inegrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

50 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-03-31

Primary Completion

2016-03-31

Completion

2016-03-31